(IBB)

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

As of the latest data available, the top three holdings in the iShares Biotechnology ETF (NASDAQ: IBB) are: These three companies collectively represent approximately 25.68% of the Biotechnology Secto...

Biotech stocks have underperformed due to sector rotation, rising rates, and regulatory pressures, but I see a contrarian opportunity emerging. A close look at the recent performance of biotech stocks...

The stock market doesn't believe the president about prescription drugs.

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...

U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...

Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.